11
CBS Journal ClubCBS Journal Club
Christopher Sharpe MD, FRCPCChristopher Sharpe MD, FRCPCR6 Transfusion MedicineR6 Transfusion Medicine
March 1, 2011March 1, 2011
22
ObjectivesObjectives• to discuss the impact of deferring female
plasma and platelet apheresis donors on blood component availability in the US
• to discuss TRALI-mitigation strategies (including the current CBS policy)
Focus of Journal ClubFocus of Journal Club “ “ Blood donations from previously Blood donations from previously
transfused or pregnant donors: a transfused or pregnant donors: a multicenter study to determine the multicenter study to determine the frequency of alloexposure ” frequency of alloexposure ”
Rios JA, Schlumpf KS, Kakaiya RM, Rios JA, Schlumpf KS, Kakaiya RM, et alet al..Transfusion 2011Transfusion 2011
44
IntroductionIntroduction• transfusion-related acute lung injury
(TRALI) is a leading cause of death due to blood transfusion
• US FDA data: - 35% of deaths due to transfusion (2008) - 30% of deaths due to transfusion (2009)
55
IntroductionIntroduction• November 2006:
- TRALI mitigation strategies implemented
widely to minimize the preparation of high-plasma volume components from donors immunized (or at risk for immunization) against white blood cell antigens
66
IntroductionIntroduction• UK data (Chapman, Transfusion 2009) - risk for highly likely or probable TRALI cases
was 15.5 cases per 1 million units of FFP issued in 1999-2004 (when both male and female plasma was transfused)
- risk for highly likely or probable TRALI cases
was 3.2 cases per 1 million units of FFP issued in 2005-2006 (when male plasma was transfused)
77
IntroductionIntroduction• UK Data: SHOT Steering Committee 2010
- plasma for transfusion is manufactured
from males since late 2003
2002: 32 cases of TRALI 2009: 14 cases of TRALI
88
Introduction
• Remaining question: - do other TRALI-mitigation steps need to
be considered aside from the complete exclusion of all female donors from the donor pool?
99
IntroductionIntroduction• CBS policy:
- defer female donors from donating transfusable plasma (unless AB plasma is required)
- use female plateletpheresis donors only if they
do not have a history of pregnancy
- female donor plasma used for fractionation
1100
Specificities of leukocyte alloantibodies in Specificities of leukocyte alloantibodies in transfusion-related acute lung injury and results of transfusion-related acute lung injury and results of
leukocyte antibody screening of blood donorsleukocyte antibody screening of blood donorsReil et al., Vox Sang 2008Reil et al., Vox Sang 2008
• Purpose: - to determine the specificities of leukocyte antibodies implicated in previous severe TRALI reactions
• Results: - 36 TRALI cases reviewed - anti-HLA class II (17 cases) - anti-HNA (12 cases; 10 with anti-HNA-3a) - anti-HLA class I (4 cases) - anti-HLA class I/II (3 cases)
1111
Specificities of leukocyte alloantibodies in Specificities of leukocyte alloantibodies in transfusion-related acute lung injury and results of transfusion-related acute lung injury and results of
leukocyte antibody screening of blood donorsleukocyte antibody screening of blood donorsReil et al., Vox Sang 2008Reil et al., Vox Sang 2008
• Results: - investigated 5332 parous female donors - 473 had leukocyte antibodies (8.9% alloimmunization rate)
- 61% had anti-HLA class I - 19% had anti-HLA class II - 12% had both anti-HLA class I and class II - 5% had anti-HNA
1122
Specificities of leukocyte alloantibodies in Specificities of leukocyte alloantibodies in transfusion-related acute lung injury and results of transfusion-related acute lung injury and results of
leukocyte antibody screening of blood donorsleukocyte antibody screening of blood donorsReil et al., Vox Sang 2008Reil et al., Vox Sang 2008
• Results: - no antibody-mediated TRALI cases were observed
following introduction of a policy of accepting transfusable plasma only from male donors, nulliparous female donors, or tested multiparous female donors without HLA antibodies
- no shortage of plasma or platelet products was encountered as a result of the restrictive strategy
1133
Specificities of leukocyte alloantibodies in Specificities of leukocyte alloantibodies in transfusion-related acute lung injury and results of transfusion-related acute lung injury and results of
leukocyte antibody screening of blood donorsleukocyte antibody screening of blood donorsReil et al., Vox Sang 2008Reil et al., Vox Sang 2008
• Conclusion: - isolated HLA-class I antibody screening is insufficient for leukocyte antibody screening
1144
Introduction
• the prevalence of human neutrophil antibodies (HNA) antibodies among US blood donors is small compared to the number with HLA antibodies (Triulzi, Transfusion, 2008)
1155
Prevalence of HLA antibodies in remotely transfused Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors (LAPS-1) or alloexposed volunteer blood donors (LAPS-1)
Kakaiya et al., Transfusion 2010Kakaiya et al., Transfusion 2010
• 7920 donors (2086 males, 5834 females) were tested for antibodies against HLA class I and HLA class II
• the prevalence of HLA class I and/or class II antibodies was similar in nontransfused (1138; 1.0%) vs. transfused men (895; 1.7%)
1166
Identification of specificities of antibodies against Identification of specificities of antibodies against human leukocyte antigens in blood donors (LAPS-1) human leukocyte antigens in blood donors (LAPS-1)
Endres et al., Transfusion 2010Endres et al., Transfusion 2010
• antibody frequencies against HLA class I and HLA class II were determined for 7920 donors (2086 males, 5834 females) with a positive antibody screen
• positive rate increased among women with 0 to 4 or more pregnancies (0.3-15.6% for anti-HLA class I and 0.4-18% for anti-HLA class II; p<0.00001)
1177
The effect of previous pregnancyThe effect of previous pregnancy and transfusion on HLA and transfusion on HLA alloimmunization in blood donors: implications for a alloimmunization in blood donors: implications for a
transfusion-related acute lung injury risk reduction strategytransfusion-related acute lung injury risk reduction strategy
Triulzi et al., Transfusion 2009Triulzi et al., Transfusion 2009 • Purpose: to determine the prevalence of HLA antibodies
in blood donors and and their relationship to previous transfusion or pregnancy
• Methods:
- 8171 volunteer blood donors were prospectively recruited by six US blood centers from December 2006 to May 2007 - donors provided a detailed history of prior pregnancies and transfusion events - donors were tested for HLA Class I and II antibodies
1188
The effect of previous pregnancyThe effect of previous pregnancy and transfusion on HLA and transfusion on HLA alloimmunization in blood donors: implications for a alloimmunization in blood donors: implications for a
transfusion-related acute lung injury risk reduction strategytransfusion-related acute lung injury risk reduction strategy
Triulzi et al., Transfusion 2009Triulzi et al., Transfusion 2009 • Results:
- HLA antibodies were detected in 17.3% of all female donors (n = 5834) and in 24.4% of those with a history of previous pregnancy (n = 3992)
- the prevalence of HLA antibodies increased in women
with more pregnancies: - 1.7% (no pregnancies) - 11.2% (one pregnancy) - 22.5% (two pregnancies) - 27.5% (three pregnancies) - 32.2% (four or more pregnancies; p < 0.0001)
1199
Introduction• Retrovirus Epidemiology Donor Study-II
(REDS-II)
- funded by NIH
- investigated the presence of antibodies to human leukocyte antigens (HLA) and/or human neutrophil antigens (HNA) among six US blood centers
2200
Blood donations from previously transfused or pregnant Blood donations from previously transfused or pregnant donors: a multicenter study to determine the frequency of donors: a multicenter study to determine the frequency of
alloexposurealloexposureRios JA, Schlumpf KS, KakaiyaRios JA, Schlumpf KS, Kakaiya RM, et al.RM, et al.
Transfusion 2011Transfusion 2011• Purpose: - to estimate the prevalence of WBC alloimmunization
according to the pregnancy and transfusion history of allogeneic blood donors at each of the REDS-II blood centers
- to compare the impact of the implementation of the aaBB TRALI mitigation strategies among six different blood centers in the US (only using male plasma for transfusion and deferring female plateletpheresis donations)
2211
Methods• data used was from Retrovirus Epidemiology
Donor Study-II (REDS-II)
• Six participating blood centers in study: - Blood Centers of the Pacific (San Francisco) - American Red Cross Blood Services Southern Region (Atlanta, GA) - New England (Massachusetts) - Hoxworth Blood Center (Cincinnati) - Institute for Transfusion Medicine (Pittsburgh) - BloodCenter of Wisconsin (Milwaukee)
2222
Methods• donation data was sent to the REDS-II central
coordinating center for compilation
• data collected from Jan 2006 – Dec 2008 - age
- sex - first-time or repeat donor status - transfusion history - pregnancy history - donation procedure (whole blood vs apheresis component) - blood donation type (allogeneic vs. autologous donation) - blood type
2233
Methods• the percentages of donations from donors with risk
factors for HLA and/or HNA alloimmunization were calculated
• the number of donations of apheresis platelets from female donors that could have HLA antibodies was calculated (according to prior pregnancy history from this study AND the proportion of female donors with positive screening test results for HLA antibodies from the LAPS-I Study)
2244
Methods• the percentages of donations resulting in
1, 2, or 3 units of apheresis PLTs at two REDS-II blood centers were used to calculate the numbers of apheresis PLTs products that could be lost if the following groups were deferred from future apheresis PLT donations:
- all female donors
- all ever-pregnant female donors - all ever-pregnant female donors with anti-HLA
2255
Methods
• the percentages of donations from donors with AB blood type were calculated from:
- all male donors - all female donors - all ever-pregnant female donors - all ever-pregnant female donors with positive screening tests for HLA antibodies
• chi-square test was performed to assess the association between the percentage of female apheresis PLT donors in 2006 compared to 2008
2266
Table 1
2277
Figure 1
2288
Table 2
2299
Figure 2
3300
Table 3A
3311
Table 3B
3322
Table 4A
3333
Table 4B
3344
Table 5
3355
Table 6
333
Discussion Discussion • study provided data on the frequency of risk factors for alloimmunization to
WBC antigens among US blood donors (transfusion and pregnancy history)
• study data allowed for an estimation of the loss of available blood components using various TRALI mitigation strategies:
- deferring all female donors would incur a 50% reduction in the number of units of whole blood available for transfusable plasma manufacturing
- deferring all female donors would incur a loss of 37% of apheresis platelet
donations
4
333
DiscussionDiscussion• only 3-4% of blood donors between 2006 and 2008 reported a history of prior transfusion
• the prevalence of HLA antibodies among blood donors appears independent of prior transfusions
- deferring donors with a transfusion history is not an effective TRALI mitigation strategy
4
333
DiscussionDiscussion• 66.7% of 95000 donations of apheresis platelets from female donors were
donated by women reporting a history of one or more pregnancies
• TRALI mitigation strategies for female apheresis platelet donors: - defer all female donors (lose 37.1% of donors)
- defer female donors who have had at least one prior pregnancy (lose 22.5% of donors)
- defer previously-pregnant females who have HLA antibodies (lose 5.4%
of donors)
4
333
DiscussionDiscussion• Strategies to make up for the deferred units from previously-pregnant
female apheresis platelet donors who have HLA antibodies (5.4%): - increase the production of platelet concentrates from whole blood - replace with male donors - replace with nulliparous female donors - replace with ever-pregnant female donors without HLA antibodies
• the institution of HLA antibody measurement in this setting is problematic
4
333
Critical AppraisalCritical Appraisal• Are the results valid? • yes: - information on what impact various TRALI mitigation strategies would have on the
availability of blood components is needed
- the volume of donor data available for analysis in this study is large (but it represents only ~8% of total donations made in the United States)
4
333
Critical AppraisalCritical Appraisal• Are the results valid?
- the methodology used to measure HLA and HNA antibodies in the REDS-II study was not stated in the current study
- bias in information collection is likely not an issue in this study since donors
volunteered relatively simple demographic information (gender, pregnancy and transfusion history)
- missing data on previous pregnancies was an issue in only a small number of donors (~ 3%)
4
333
Critical AppraisalCritical Appraisal• Are the results valid? - it appears safe to assume that females that have not been
previously-pregnant will not have HLA antibodies - is it safe to accept that prior transfusion is not a significant
risk factor for WBC alloimmunization?
4
333
Critical AppraisalCritical Appraisal• Are the results valid? - not every country or jurisdiction may possess the capacity to measure HLA or HNA antibodies in their donor
population - plateletpheresis units are not usually split into multiple units in Canada - double-RBC collections are not usual in Canada (yet)
4
333
Critical AppraisalCritical Appraisal• What are the results?
In the Unites States: - deferral of all female apheresis PLT donors: 37.1% loss of total donations
- deferral of all female apheresis PLT donors with a prior pregnancy history: 22.5% loss of total donations
- deferral of all female apheresis PLT donors with a prior pregnancy history and positive screening results for HLA antibodies: 5.4% loss of total donations
4
4455
How Can I Apply The Results How Can I Apply The Results To Patient Care?To Patient Care?
• Current CBS policy:
- defer female donors from donating transfusable plasma (unless AB plasma is required)
- female donor plasma used for fractionation - use female plateletpheresis donors only if they
do not have a history of pregnancy
4466
TRALI Cases Reported to CBS TRALI Cases Reported to CBS 2001-2001-20092009
• PMP (predominantly male plasma) used for transfusion October 2007
4466
Year 2001 2002 2003 2004 2005 2006 2007 2008 2009
Definite/Possible TRALI
6 6 6 16 14 21 36 19 12
4477
TRALI Cases Reported to CBS TRALI Cases Reported to CBS 2001-2001-20092009
• component breakdown for definite/possible TRALI cases
4477
Year Total RBC PLT Plasma Mixed
2007 36 18 3 7 8
2008 19 11 3 2 3
2009 12 7 1 1 3
4488
CBS Data
4499
CBS Data
5500
CBS Data
5511
CBS Data
5522
CBS Data
5533
CBS Data
5544
CBS Data
16161616
Questions or Questions or comments?comments?